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Objective: The aim of this study is to evaluate the long-term outcome of ovarian recurrent granulosa cell
tumors (GCTs) in a large series of patients treated in Taiwanese Gynecologic Oncology Group (TGOG)
centers and to deﬁne the prognostic parameters for survival.
Materials and methods: A retrospective multi-institutional review of patients with recurrent ovarian
GCTs treated in TGOG centers was conducted. The clinical and pathological characteristics, treatment,
and outcomes of patients with ovarian recurrent GCTs were analyzed using Kaplan-Meier and Cox
proportional hazards analyses to determine the predictors for survival.
Results: A total of 44 patients from 16 medical centers were identiﬁed between January 1994 and
December 2010. The median disease-free survival (DFS), postrecurrence survival, and overall survival
(OS) were 61.5 months (range, 3.7e219.3 months), 55.8 months (range, 4.6e193.7 months), and 115.3
months (range, 17.2e390.6 months), respectively. In multivariate analysis, DFS (> 61.5 months
versus  61.5 months, hazard ratio (HR) 0.15, 95% conﬁdence interval (CI) 0.03e0.78, p ¼ 0.024) at the
initial operation after diagnosis of relapse was the only predictor that correlated with OS.
Conclusion: DFS after the initial operation was the only important predictor for overall survival in pa-
tients with recurrent GCTs, regardless of treatment, suggesting that the natural behavior of the tumor is a
critical factor for patients with recurrent GCTs.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
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Table 1
Patient and tumor characteristics at initial diagnosis (n ¼ 44).
Characteristic
Age (y) 44 (20e73)
Nullipara 9 (20.5)
Multipara 35 (79.5)
Premenopause 27 (61.4)
Postmenopause 17 (38.6)
Body mass index 23.1 (16.0e32.9)
Associated medical illnessa
Hypertension 9 (20.5)
Diabetes mellitus 7 (15.9)
Others 5 (11.4)
Thyroid 2 (4.5)
Depression 1 (2.3)
Stroke 1 (2.3)
Systemic lupus erythematous 1 (2.3)
Associated with medical illness
Yes 14 (31.8)
History of previous hysterectomy
Yes 2 (4.5)
Symptoms
Abdominal pain and fullness 17 (38.6)
Abdominal mass 8 (18.2)
Abnormal bleeding 18 (40.9)
Symptoms
Yes 37 (84.1)
Stage
IA 22 (50.0)
IC 13 (29.5)
IIIA 1 (2.3)
IIIC 6 (13.6)
IV 2 (4.5)
Stage
 I 35 (79.5)
> I 9 (20.5)
Tumor size (cm) 12 (1e35)
Bilaterality
Yes 20 (45.5)
Laparoscopy 8 (18.2)
Exploratory laparotomy 36 (81.8)
USO 20 (45.5)
BSO and TH 8 (18.2)
Complete staging surgery 16 (36.4)
Residual tumor
Yes 7 (15.9)
Adjuvant chemotherapy
Yes 14 (31.8)
Chemotherapy regimen
BEP 13 (29.5)
VAC 1 (2.3)
Chemotherapy cycles
0 30 (68.2)
1 1 (2.3)
3 7 (15.9)
4 2 (4.5)
6 4 (9.1)
Chemotherapy cycles
1e3 8 (18.2)
> 3 6 (13.6)
Disease-free survival (mo) 61.5 (3.7e219.3)
Overall survival (mo) 111.2 (17.2e390.6)
Disease-free survival (mo)b 62.1 (3.7e219.3)
Overall survival (mo)b 115.3 (17.2e390.6)
Data are presented as median (range) or n (%).
BEP ¼ bleomycin, etoposide, cisplatin; BSO ¼ bilateral salpingo-oophorectomy;
TH ¼ total hysterectomy; USO ¼ unilateral salpingo-oophorectomy;
VAC ¼ vinblastine, adriamycin, and cisplatin.
a Some patients had more than one medical disease.
b One patient died from lung cancer and was excluded from this analysis.
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Ovarian adult-type granulosa cell tumors (GCTs) are derived
from ovarian sex-cord stromal hormone-secreting tumors; they are
rare and characterized as having slow, indolent growth, and late-
recurrence [1e3]. The prognostic factors for GCTs include older
age, advanced stage (Stage IIeIV), large tumor size, high mitotic
index, tumor rupture, and the presence of residual tumor after
initial surgery [4e21]. These prognostic factors are frequently
identiﬁed with tumor recurrence, not survival, after the initial
treatment of primary GCTs. Due to the above-mentioned charac-
teristics of GCTs, it is difﬁcult to obtain data on long-term follow-up
of a large number of patients. The treatment and outcome of
recurrent GCTs is still uncertain. Only a few reports are available in
the literature and the number of participants in these studies was
small [22e28]. The current study was conducted from 16 medical
centers in Taiwan to investigate the outcomes of patients with
recurrent GCTs.
Materials and methods
This was a subsequent study of the original design from the
Taiwanese Gynecologic Oncology Group (TGOG) study [5,6] to
investigate the outcome of patients with GCTs (TGOG-3001A) [5],
based on 16 medical centers in Taiwan [5,6]. All GCTs were
conﬁrmed by central pathological review. The study period was
between January 1994 and December 2010 and only patients with
recurrent GCTs were included (TGOG-3001B). Approval for this
study was obtained from the institutional review boards of all
medical centers involved. Part of the data (36 patients) have pre-
viously been published [5]. Patient characteristics included clinical
and pathological parameters, and treatment for either primary or
recurrent tumors. Data collection included records of the initial
operation for the primary tumors (GCTs) and secondary treatment
for the recurrent GCTs. Disease-free survival (DFS) was calculated
from the date of the initial operation for the primary GCTs to the
date of relapse. Postrecurrent survival was calculated from the date
of the diagnosis of relapse to the date of death or the date of the last
follow-up, and overall survival (OS) was calculated from the date of
diagnosis to the date of death or the date of the last follow-up. To
determine an appropriate decision point for the continuous data,
such as age, body mass index (BMI), tumor size, DFS, and post-
recurrent survival, the receiver operating characteristic was used
[29]. Statistical analysis was conducted using SPSS version 18 (SPSS,
Inc., Chicago, Il, USA). A p value < 0.05 was deﬁned as statistically
signiﬁcant; all tests were 2-tailed. The recurrence curves were
calculated using the Kaplan-Meier method, and the log-rank test
was used to compare the recurrence curves. Univariate and
multivariate analyses were performed using the Cox regression
model, and Pearson's Chi-square test and Fisher's exact test were
used to compare the differences in proportions.
Results
A total of 44 patients had recurrent GCTs. At initial diagnosis,
most patients were multipara (79.5%), symptomatic (84.1%), at an
early stage (Stage I: 79.5%), and treated with exploratory laparot-
omy (81.8%) and incomplete staging surgery (63.5%), and were
without adjuvant chemotherapy (n¼ 30, 68.2%). Themost common
chemotherapy regimen was bleomycin, etoposide, and cisplatin
(BEP) regimen (13/44). The median OS was 111.2 months, ranging
from 17.2 months to 390.6 months for all patients, and 115.3
months, ranging from 17.2 months to 390.6 months, when one
patient who died of lung cancer was excluded. The median DFS was
61.5 months, ranging from 3.7 months to 219.3 months (Table 1).Most patients had peritoneal recurrence (88.6%), but did not
have symptoms (61.4%); therefore, these symptomless patients
were found accidentally during the follow-up. These recurrent
patients were mainly treated with surgery-based therapy (77.3%),
including nine patients (20.5%) with surgery alone and the
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as chemotherapy and radiation. Up to two-thirds of patients (65.9%)
were treated with various kinds of chemotherapies, the most
frequent regimen of chemotherapy was BEP. If the patients had
been treatedwith a BEP regimen, bleomycinwas avoided and only a
combination of etoposide and cisplatin was used. During the
follow-up,14 patients died: 13 deaths were disease-related and one
patient died of lung cancer. The overall mortality rate of the pa-
tients with recurrent GCTs was 31.8% (14/44) and 30.3% (13/43),
respectively. The median postrecurrent survival was 55.8 months,
ranging from 4.6 months to 193.7 months (Table 2).
In terms of prognostic factors at the initial diagnosis, univariate
analysis showed that only BMI and DFS were correlated with OS.
However, DFS alone contributed to OS in recurrent patients. If the
patients had a DFS of > 61.5 months, the risk of disease-related
death was signiﬁcantly decreased [hazard ratio (HR), 0.15, 95%
conﬁdence interval (CI), 0.03e0.78; p ¼ 0.024] (Table 3).
The characteristics of patients when they were diagnosed as
having recurrence was also analyzed (Table 4). Only post-
recurrence survival contributed to OS in these recurrent patients.
If the patients had postrecurrence survival of > 51.8 months after
secondary treatment for recurrent tumors, the risk of disease-
related death signiﬁcantly decreased (HR, 0.10; 95% CI,
0.02e0.53; p ¼ 0.007), suggesting that complete resection for aTable 2
Patient and tumor characteristics at recurrence (n ¼ 44).
Characteristic
Age (y) 50.1 (22e75)
Symptoms
Yes 17 (38.6)
Asymptomatic 27 (61.4)
Metastatic site
Peritoneal cavity (upper and low) 39 (88.6)
Liver parenchyma 6 (13.6)
Lymph node 4 (9.1)
Bone 1 (2.3)
Treatment
Nil 2 (4.5)
Surgery alone 9 (20.5)
Chemotherapy alone 8 (18.2)
Surgery and chemotherapy 23 (52.3)
Surgery and concurrent chemoradiation 2 (4.5)
Surgery-based therapy
Yes 34 (77.3)
No 10 (22.7)
Chemotherapy regimen
Nil 12 (27.3)
BEP 21 (47.7)
EP 3 (6.8)
PC 5 (11.4)
Paclitaxel 1 (2.3)
Cisplatin 2 (4.5)
Chemotherapy regimen
Single (paclitaxel or cisplatin) 3 (6.8)
Combination (BEP or EP or PC) 29 (65.9)
Chemotherapy regimen
BEP or EP 24 (54.5)
PC or paclitaxel 6 (13.6)
Cisplatin 2 (4.5)
Cycles of chemotherapy
1e3 10 (22.7)
> 3 22 (50.0)
Overall survival rate
Death 14 (31.8); 13 (30.3)a
Alive 30 (68.2); 30 (69.7)a
Postrecurrence survival (mo)a 55.8 (4.6e193.7)
Data are presented as median (range) or n (%).
BEP ¼ bleomycin, etoposide, cisplatin; EP ¼ etoposide and cisplatin; PC ¼ paclitaxel
and cisplatin.
a One patient died from lung cancer and was excluded from this analysis.recurrent tumor might provide a better opportunity of survival
for patients with recurrent GCTs.
Discussion
The typical clinical scenario of patients with GCTs is usually a
middle-aged female presenting with a pelvic mass or endocrine
syndrome due to a functional tumor, especially estrogen secretion
[30,31]. This was consistent with the ﬁndings in the current study
patients at the initial operation, since symptoms, such as abdom-
inal pain, pelvic mass, and irregular bleeding occurred in most
patients (> 80%). However, < 40% of recurrent patients presented
symptoms; that is to say, > 60% of patients were identiﬁed at the
routine postoperative follow-up and were detected accidentally.
In contrast to epithelial ovarian cancer, GCTs are characterized
by slow, indolent growth with a tendency toward later recurrence
[30], As much as 70e90% of GCTs were diagnosed at Stage I [26],
and in a TJOG studywith a large sample size (n¼ 176), nearly 80% of
patients were at Stage I [5]. Low staging at the initial operation
confers an excellent prognosis, with a 5-year OS rate reported to be
75e96.5%, and a 10-year OS rate reported as 94.1% [5]. However, the
OS rates dropped to 55e75% and 22e50% for Stages II and III/IV,
respectively [31]. In this study, nine patients were in an advanced
stage (9/44, 20.5%), and most patients were Stage I (79.5%), which
was very close to the above-mentioned original stage of the pa-
tients at the initial operation [5].
The median time from the initial operation to the detection of
recurrence was 61.5 months, ranging from 3.7 months to 219.3
months (Table 1). In agreement with previous reports, frequent
sites of recurrence included the upper abdomen (55e70%) and
pelvis (30e45%) [2,23,26e28,31]. In this study, recurrence at the
abdominal cavity was most common (88.6%). With respect to the
sites of recurrence of primary and recurrent GCTs, Fotopoulou et al
[23] showed in a recent evaluation that tumor dissemination
pathways followed by primary and recurrent GCTs differed signif-
icantly, based on the higher rates of multivisceral tumor involve-
ment in disease recurrence. They found that a primary presentation
of extrapelvic involvement with peritoneal carcinomatosis was
rare. Lee et al [26] also showed that the most common sites of
recurrence were the pelvic cavity, followed by the liver and the
intestine, but the vast majority of the recurrent cases presented
with extrapelvic metastases. In this study, more than two-thirds of
the patients with intraperitoneal recurrence had upper abdomen
involvement. In addition, 23.3% of patients had multi-organ
involvement.
In terms of nodal involvement in patients with recurrent GCTs,
Brown et al [32], in an attempt to describe the incidence of nodal
involvement in patients with recurrent GCTs, could show that only
six (5.1%) out of a total of 117 patients whose disease eventually
recurred had nodal metastases at the time of recurrence. In fact,
three of these six patients had negative lymph nodes at initial
staging [32]. Consistent with the rarity of nodal involvement in
GCTs at both the initial operation and also in recurrence, just six
patients (13.6%) had recurrence on the lymph nodes in this study.
The concept of the management of recurrent GCTs is still
controversial. Similar to epithelial ovarian cancers, intraperitoneal
recurrence of GCTs is most common. Therefore, in contrast to the
clear role of adjuvant chemotherapy in recurrent epithelial ovarian
cancer, the surgery for recurrent GCTs might be a better alternative
[28], due to the characteristically slow, indolent pattern of pro-
gression, even for recurrent GCTs. The value of surgery is mainly
based on the initial operation for GCTs. For example, in a comparison
of the outcomes of patients with GCTs before and after 1988,
H€olscher et al [11] found signiﬁcant improvements in 5-year and 10-
year OS, from 55.8% to 89.1% and from 42.8% to 85.2%, respectively.
Table 3
Univariate and multivariate Cox regression analyses at the initial diagnosis (n ¼ 43).
Characteristics No. Univariate analysis Multivariate analysis
HR (95% CI) p HR (95% CI) p
Age
 45 24 1 (Ref) 1 (Ref)
> 45 19 2.100 (0.681e6.471) 0.196 1.877 (0.382e9.221) 0.438
Nullipara
No 34 1 (Ref)
Yes 9 0.687 (0.151e3.117) 0.627
Menopause
No 27 1 (Ref)
Yes 16 2.585 (0.840e7.956) 0.098
Body mass index
 23.6 25 1 (Ref) 1 (Ref)
> 23.6 18 3.684 (1.109e12.237) 0.033 2.839 (0.666e12.097) 0.158
Associated with medical illness
No 30 1 (Ref)
Yes 13 0.891 (0.273e2.904) 0.848
History of hysterectomy
No 42 1 (Ref)
Yes 1 0.048 (0.000e2.156E7) 0.765
Symptoms
No 7 1 (Ref)
Yes 36 0.570 (0.150e2.169) 0.410
Stage
IA 22 1 (Ref)
IC 12 5.048 (1.194e21.350) 0.028
IIIA 1 0.000 0.991
IIIC 6 4.432 (0.700e28.047) 0.114
IV 2 6.354 (1.015e39.770) 0.048
Stage
0.352
 I 34 1 (Ref) 1 (Ref)
> I 9 2.221 (0.682e7.235) 0.185 2.280 (0.402e12.922)
Bilaterality
No 24 1 (Ref)
Yes 19 2.635 (0.847e8.201) 0.094
Tumor size (cm)
 11.5 21 1 (Ref)
> 11.5 22 0.654 (0.214e1.994) 0.455
Laparoscopy
No 35 1 (Ref)
Yes 8 1.760 (0.483e6.416) 0.392
Complete staging surgery
No 28 1 (Ref)
Yes 15 2.207 (0.731e6.661) 0.160
Residual tumor
No 36 1 (Ref)
Yes 7 1.904 (0.522e6.941) 0.329
Adjuvant chemotherapy
No 29 1 (Ref) 1 (Ref)
Yes 14 2.128 (0.713e6.354) 0.176 1.348 (0.313e5.811) 0.688
Chemotherapy regimen
Nil 29 1 (Ref)
BEP 13 1.807 (0.572e5.713) 0.313
VAC 1 51.074 (3.049e855.455) 0.006
Chemotherapy cycles
0 29 1 (Ref)
1e3 8 1.475 (0.378e5.762) 0.576
> 3 6 3.797 (0.946e15.234) 0.060
Disease-free survival (mo)a
 61.5 21 1 (Ref) 1 (Ref)
> 61.5 22 0.201 (0.054e0.753) 0.017 0.150 (0.029-0.779) 0.024
BEP ¼ bleomycin, etoposide, cisplatin; HR ¼ hazard ratio; VAC ¼ vinblastine, adriamycin, and cisplatin.
a One patient died from lung cancer and was excluded from this analysis.
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attributed partly to advances in treatment, such as improved sur-
gery without residual tumors, and ﬁnally concluded that surgery
remains the cornerstone of treatment. In addition, many studies
showed favorable outcomes for GCTs after complete excision,
without residual tumor at the initial operation [2,5,7,9,11,26].
With respect to surgical experience with recurrent disease,
data are far more limited. Fotopoulou et al [23] used amultivisceral operative approach, including extensive peri-
tonectomy, intestinal or diaphragmatic resection, splenectomy,
and partial hepatectomy/pancreatectomy, and found that 85.2% of
recurrent patients could be operated on tumor-free. This concept
was also supported by a study from Korea, where > 80% of
recurrent patients could be optimally debulked during the second
operation [26]. In a much smaller study, Chua et al [22] reported
prolonged survival following a maximal cytoreductive effort for
Table 4
Univariate and multivariate Cox regression analyses after recurrence (n ¼ 43).
Characteristics No.a Univariate analysis Multivariate analysis
HR (95% CI) p HR (95% CI) p
Age (y)
 52 24 1 (Ref) 1 (Ref)
> 52 19 2.317 (0.706e7.608) 0.166 2.063 (0.582e7.314) 0.262
Symptoms
No 27 1 (Ref)
Yes 16 1.541 (0.515e4.606) 0.439
Only peritoneal invasion
No 5 1 (Ref)
Yes 38 1.033 (0.223e4.782) 0.967
Metastasis to > 1 organ
No 33 1 (Ref) 1 (Ref)
Yes 10 3.311 (0.922e11.889) 0.066 0.954 (0.223e4.083) 0.949
Treatment
Surgery alone 9 0.374 (0.048e2.925)
Others 34 1 (Ref) 0.349
Treatment
Chemotherapy alone 8 0.516 (0.111e2.396)
Others 35 1 (Ref) 0.398
Surgery-based therapy
No 9 1 (Ref)
Yes 34 1.160 (0.310e4.341) 0.825
Adjuvant chemotherapy
No 11 1 (Ref) 1 (Ref)
Yes 32 1.709 (0.377e7.740) 0.487 1.386 (0.291e6.613) 0.682
Chemotherapy regimen
Nil 11 1 (Ref)
BEP 21 1.568 (0.325e7.578) 0.576
EP 3 9.554 (1.212e75.303) 0.032
PC 5 1.743 (0.244e12.451) 0.580
Paclitaxel 1 0.000 0.990
Cisplatin 2 0.000 0.994
Chemotherapy regimen
Nil 11 1 (Ref)
Single (paclitaxel or cisplatin) 3 0.000 0.985
Combination (BEP or EP or PC) 29 1.901 (0.420e8.602) 0.404
Chemotherapy regimen
Nil 11 1 (Ref)
BEP or EP 24 1.939 (0.418e8.995) 0.398
PC or paclitaxel 6 1.257 (0.175e9.052) 0.820
Cisplatin 2 0.000 0.987
Chemotherapy cycles
0 11 1 (Ref)
1e3 10 2.859 (0.571e14.316) 0.201
> 3 22 1.166 (0.226e6.018) 0.855
Postrecurrence survival (mo)
 51.8 20 1 (Ref) 1 (Ref)
> 51.8 23 0.086 (0.020e0.368) 0.001 0.101 (0.019e0.529) 0.007
BEP ¼ bleomycin, etoposide, cisplatin; EP ¼ etoposide and cisplatin; PC ¼ paclitaxel and cisplatin.
a One patient died of lung cancer and was excluded from this analysis.
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were still alive 10e95 months after treatment, with no evidence of
disease. Although Fotopoulou's group [23] and Lee's group [26]
both showed a very high rate (> 80%) of successful cytor-
eduction (optimally debulking surgery) in these recurrent-GCT
patients with multifocal lesions, there was no doubt that surgi-
cal cytoreduction during relapse is more challenging and involves
a multivisceral approach [23]. In fact, Uygun's group [27] found
that only two of 11 patients could undergo surgical tumor
debulking. In the current study, up to 80% of patients were initially
treated with surgery for recurrent tumors, and among this group,
one-quarter of the recurrent CGTs (26.5%, 9/34) were treated with
surgery alone (20.5% of all recurrent patients, Table 2). Both
treatment approaches contributed to the acceptable outcome,
since more than two-thirds (68.2% or 69.7%) of recurrent patients
were still alive after secondary treatment. Although surgery alone
or surgery-based therapy seemed not to have a statisticallysigniﬁcant effect on OS (Table 4), it appears that complete resec-
tion of a recurrent tumor might provide the best opportunity for
patient survival.
In terms of adjuvant therapy, such as chemotherapy, radiation,
or others, there is an absence of agreement on the best and most
favorable regimen for recurrent GCTs, although BEPmight be one of
the best choices, based on the relatively better response rate,
ranging from 51% to 90% at the advanced-stage or in recurrent
patients [22,33e35]. However, the effectiveness of this treatment
remains poor, with a median DFS of only 14e24months [33e35]. In
this study, > 80% of the patients had been treated with BEP therapy,
either at the initial operation or at recurrence. One patient was
treated with a vinblastine, Adriamycin, and cisplatin (VAC) regimen
at the initial operation, ﬁve patients were treated with paclitaxel
and cisplatin, two patients with single-agent cisplatin, and one
patient with paclitaxel. The role of paclitaxel in the treatment of
GCTs is still uncertain, although one report concluded that
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the ovary and may be less toxic than BEP, and suggested that
combined paclitaxel and platinum chemotherapy warrants further
investigation [36]. However, in this study, neither the chemo-
therapy regimens nor the cycles of chemotherapy ( 3 cycles
versus > 3 cycles) made a statistically signiﬁcant contribution to OS
either at the initial operation or when treating recurrence (Tables 3
and 4). With regard to radiation or other therapies, such as hor-
monal therapies and antivascular agent therapies, that have been
reported in the literature [22,25,37e41], the response rate was 43%
(6/14) in a radiation group [37] and 40% (2/5) in a leuprolide acetate
treatment group [38], respectively. However, these reports might
be considered as personal experiences [25,39e41].
There are some limitations in the current study. Firstly, this was
a multicenter, retrospective study, so the selection bias inherent to
this kind of design may have been introduced into the study.
Although the best way to avoid or minimize this bias is to conduct a
prospective randomized study, this was not feasible due to the
characteristics of GCTs, including their rarity, slow and indolent
growth, and late recurrence. A retrospective study with a large data
set is still the accepted way to investigate this kind of problem.
Secondly, the patient sample size in this study was relatively small.
Despite these limitations, the data presented here is still useful,
since it may be the ﬁrst attempt and largest series to report out-
comes among a Taiwanese population (in Taiwan).Conclusion
From the study ﬁndings, surgery-based therapy could be
considered as the primary choice for patients with recurrent GCTs,
since the vast majority of recurrent tumors involve the abdominal
cavity, maximal cytoreduction with a curative intent via a multi-
visceral operative approach for these patients could be attempted
at ﬁrst. In addition, it was found that the tumor behavior of GCTs
might be one of the most important critical factors impacting
prognosis, as DFS at the initial operation (> 61.5 months) was the
only contributor to OS in recurrent GCT patients.Conﬂicts of interest
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